Illumina Posts 5% Revenue Growth, Launches TSO 500 v2 and DRAGEN v4.4
Illumina’s fourth-quarter revenues rose 5% year-over-year to $1.16 billion, boosting adjusted operating margin to 63.7% despite a 40-basis-point gross-margin drag from tariffs. The company launched TSO 500 v2, won Japan clearance for DRAGEN v4.4 and now trades at a forward price-to-sales ratio of 4.08 versus its one-year median of 3.53.
1. Q4 Financial Results
Illumina’s fourth-quarter revenues rose 5% year-over-year to $1.16 billion, driven by higher clinical consumable sales, strong NovaSeq X placements and growth in China. Adjusted operating margin expanded by 64 basis points to 63.7%, while non-GAAP gross margin dipped 40 basis points to 67% due to a 205-basis-point tariff impact.
2. Product Innovations
The company introduced TSO 500 v2, enhancing its next-generation sequencing oncology portfolio with streamlined workflows and expanded biomarker coverage. It also secured regulatory clearance in Japan for DRAGEN v4.4 oncology applications and is collaborating on companion diagnostics for KRAS alterations with global pharmaceutical partners.
3. Valuation and Market Position
Illumina trades at a forward 12-month price-to-sales ratio of 4.08, above its one-year median of 3.53, reflecting market confidence in its product pipeline and cost reduction measures. Shares have declined 7.1% year-to-date amid broader sector pressures.
4. Analyst Outlook
The stock holds a consensus Hold rating with an average price target of $133.74, implying an 8.8% upside. Continued investments in NGS technologies and global regulatory approvals may support further valuation gains.